Guardant Health (GH) to Release Quarterly Earnings on Thursday

Guardant Health (NASDAQ:GH) is expected to release its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to post earnings of ($0.40) per share and revenue of $314.23 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Guardant Health Stock Down 1.0%

Shares of NASDAQ GH opened at $150.75 on Thursday. Guardant Health has a 52-week low of $40.35 and a 52-week high of $174.08. The firm has a fifty day moving average of $137.33 and a 200-day moving average of $111.36. The stock has a market capitalization of $19.99 billion, a PE ratio of -44.47 and a beta of 1.59.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Royal Bank Of Canada assumed coverage on Guardant Health in a research report on Thursday, June 11th. They issued an “outperform” rating and a $185.00 target price on the stock. Evercore reissued an “outperform” rating and set a $200.00 price target on shares of Guardant Health in a research report on Monday, July 6th. Piper Sandler set a $127.00 price target on Guardant Health in a research note on Thursday, May 21st. UBS Group set a $150.00 price objective on Guardant Health in a report on Wednesday, June 24th. Finally, Canaccord Genuity Group lifted their price objective on Guardant Health from $135.00 to $205.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $160.04.

Insiders Place Their Bets

In related news, CEO Amirali Talasaz sold 210,000 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $109.89, for a total transaction of $23,076,900.00. Following the completion of the sale, the chief executive officer directly owned 1,886,504 shares of the company’s stock, valued at approximately $207,307,924.56. This represents a 10.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Chris Freeman sold 24,406 shares of the stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $118.67, for a total value of $2,896,260.02. Following the completion of the sale, the insider owned 60,034 shares of the company’s stock, valued at approximately $7,124,234.78. This represents a 28.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 708,565 shares of company stock worth $90,556,597. 5.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Guardant Health

Several institutional investors and hedge funds have recently modified their holdings of the stock. Mercer Global Advisors Inc. ADV raised its holdings in shares of Guardant Health by 12.7% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 4,357 shares of the company’s stock valued at $445,000 after buying an additional 490 shares during the period. Mackenzie Financial Corp boosted its holdings in Guardant Health by 57.6% in the 4th quarter. Mackenzie Financial Corp now owns 36,023 shares of the company’s stock worth $3,617,000 after acquiring an additional 13,172 shares during the period. Fuller & Thaler Asset Management Inc. boosted its holdings in Guardant Health by 3.0% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock worth $249,398,000 after acquiring an additional 72,162 shares during the period. XTX Topco Ltd grew its position in Guardant Health by 568.0% in the fourth quarter. XTX Topco Ltd now owns 23,695 shares of the company’s stock valued at $2,420,000 after acquiring an additional 20,148 shares in the last quarter. Finally, Voloridge Investment Management LLC acquired a new stake in Guardant Health in the fourth quarter valued at approximately $10,130,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.